CLDI Calidi Bio Company Cash on Hand

CLDI (Calidi Biotherapeutics, Inc.) - company brandmark

Calidi Biotherapeutics (CLDI) faces high biomaterial costs and early-stage research risks; however, its proprietary tumor drug delivery system creates potential for pricing power. The company is currently focusing on primary trials to attract major partners. The cash reserve history reflects liquidity dynamics, where the current level is 0.00, determining the business's financial stability.

CLDI - Calidi Biotherapeutics Company Cash Funds over the range 02/21/2024 - 11/21/2026

Summary analytical data breakdowns for Calidi Biotherapeutics, Inc. (CLDI)

- stock quotes and analyst forecast:
Summary company analysis:Calidi Biotherapeutics
Signature product of calidibio.com

This indicator determines the current solvency of the business through daily monitoring of liquid assets. The calculation focuses on the actual volume of funds, excluding the time lags of quarterly reporting to assess financial autonomy. The dynamics of cash on hand demonstrate the company's ability to fund operating activities without external borrowing. For Calidi Biotherapeutics (CLDI), this reserve is critically important during the development of oncolytic platforms. High liquidity ensures the vendor's independence during the commercialization of patents, guaranteeing long-term dominance in the cancer therapy market.

Direct competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|SELLAS Life Sciences Group - Company Cash Volume|ACTU - Company Cash Volume|CTOR: Company Cash Volume|Company Cash Reserve TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Company Cash Volume|Fate Therapeutics, Inc. (FATE) - Company Liquid Assets|Company Cash on Hand WHWK (Aadi Bioscience, Inc.)|Company Liquid Assets TScan Therapeutics, Inc.|Company Cash Volume CSBR (Champions Oncology Corp)|Company Total Cash Amount XBIT (XBiotech USA)|CVM - Company Cash Funds|Company Cash Balance OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Company Cash Funds|ARTV: Company Total Cash Amount|ANL (adlainortye.com) - Company Cash Volume|VERU: Company Cash Balance|Company Cash on Hand TPST (Tempest Tx)|Company Cash on Hand Xilio XLO|Company Cash Volume RENB (Renovaro)|Company Cash Volume Mural Bio MURA|Kairos Pharma Ltd - Company Cash Volume|OnKure Therapeutics (OKUR) - Company Cash on Hand|GDTC: Company Cash Volume|Curis Inc. - Company Cash Balance|Company Cash Funds apollomicsinc.com|THAR: Company Cash Balance|Company Cash Funds Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Company Cash Balance|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds